Update for the MRCP: Self-assessment Based on Recent Key Pages in Medical Literature v. 2

CONTENTS Questions Basic science, immunology and genetics 1. Mechanisms of cell death 2. T cell activation 3. T helper (Th2) cells 4. Chemokines 5, 6. Chemokines and HIV-1 receptors 7. IGE in asthma 8. Allergen immunotherapy 9. Vaccination for hepatitis B virus (HBV) 10. Flow cytometry 11. The human genome project 12. Neurogenetics 13. The mitochondrial genome 14. Prothrombin-gene G20210A mutation 15. Nutritional requirements Pharmacology and drug development 16. Drug development 17. The yellow card scheme for reporting suspected adverse reactions 18. Study designs 19. Concerning clinical trials 20. Cytochrome P450 enzymes 21. Oral bioavailability of drugs augmented by grapefruit juice Therapeutics 22, 23. Prolongation of the QT interval 24. Inhaled beclomethasone dipropionate 25. Cyclo-oxygenase (COX) 26. Sildenafil 27. The new epilepsy drugs 28. Drug treatments for depression 29. Drug treatment of Alzheimers disease 30. 5 fluorouracil 31. Paclitaxel 32. Doxorubicin induced cardiomyopathy 33. Ecstasy 34. Cannabis 35. Carbon monoxide poisoning 36. Drug induced hypokalaemia 37. Treating a patient with glucocorticoids Neurology 38. Haematological causes of acute stroke 39. Status epilepticus 40. Friedreichs ataxia 41. diabetic peripheral neuropathy 42. Parkinsons disease 43. Neurosurgical treatments of Parkinsons disease 44. Trinucleotide repeat disorders 45. Diagnosis and management of migraine 46. Pathology of migraine 47. Management of headache Respiratory medicine 47. Brittle asthma 48. Bronchial asthma 50. Alpha antitrypsin (AAT) 51, 52. Pulmonary fibrosis 53. Nebuliser therapy 54. Primary pulmonary hypertension 55. Lung volume reduction surgery 56. Lung transplantation Endocrinology 57. Causes of hirsutism in women 58. Polycystic ovary syndrome 59. Endocrine hypertension 60. Phaeochromocytoma 61. Multiple endocrine neoplasia (MEN) 62, 63. Type 2 diabetes mellitus 64. Hypothyroidism 65, 66. Common causes of primary hypothyroidism 67. Adult growth hormone deficiency (GHD) 68. Carcinoid tumours Cardiology 69. Cardiac physiology 70. Unstable angina and non-Q wave myocardial infarction 71. Ventricular fibrillation (VF) 72, 73. Chronic heart failure 74. Ischaemic heart disease 75. Antiplatelet agents in coronary artery disease 76. Arrhythmogenic right ventricular dysplasia (ARVD) 77. Right ventricular infarction Gastroenterology 78. Primary biliary cirrhosis 79. Acute pancreatitis 80. Barretts oesophagus 81. Management of obesity 82. Hepatitis A infection 83. Haemochromatosis 84. Assessment of nutritional status 85. Nutritional supplementation 86. Patient presenting with general malaise as a result of short bowel syndrome 87. Management of gastro-oesophageal reflux disease 88, 89 Coeliac disease Nephrology 90. The nephrotic syndrome 91, 92. Solid organ transplantation 93. Atheromatous renovascular disease 94. During pregnancy 95. Kidney stones 96. Acute renal failure 97. End-stage renal failure 98. Management of rhabdomyolysis 99. IgA nephropathy Infectious diseases 100 Leprosy 101. Parasite presentation 102. Pathology mediated by exotoxins 103. Nematodes that migrate through the lung 104. Diseases transmitted by specific vectors 105. Relative contraindications to the use of antimalarial drugs 106. Clinical diagnostic methods of choice 107. Infections 108. Antimicrobials HIV 109. Clinical features of acute HIV-1 infection 110. Pathogeneisis of acute HIV-1 infection 111. Effect of HIV infection on the immune system 112. Immune reconstitution in HIV positive patients treated with highly active antiretroviral therapy (HAART) 113. British HIV association (BHIVA) guidelines for the treatment of HIV-1 infection 114. Treatment of HIV infected patients with highly active antiretroviral therapy (HAART) 115. Reservoirs of HIV-1 in patients receiving highly active antiretroviral therapy (HAART) 116. Adverse effects of antiretroviral therapy 117. Resistance to antiretroviral drugs Oncology 118, 119. Radiotherapy 120. Adjuvant chemotherapy 121. Immunotherapy 122. Tamoxifen 123. Screening 124 Non small cell lung cancer 125. High grade B cell non Hodgkins lymphoma 126. Control of cancer pain Haematology 127. Patients with multiple myeloma 128. Patients with sickle cell disease 129. Heparin-induced thrombocytopenia (type 2) 130. High homocysteine levels 131. Chronic myeloid leukaemia (CML) 132. Essential thrombocytopenia 133. Severe haemophilia A 134. Human T-cell leukaemia (HTLV) viruses 135. Acute myeloid leukaemia (AML) Rheumatology 136. Anti-neutrophil cytoplasmic antibodies (ANCA) 137. Scleroderma 138. HIV infection compared to the normal population 139. Mixed cryoglobulinaemia 140. Poor prognostic markers in patients presenting with rheumatoid arthritis 141. Bone mineral density (BMD) Dermatology 142. Acne vulgaris 143. Alopecia 144. Atopic eczema 145. Pyoderma gangrenosum 146. Mycosis fungoides 147. Psoriasis 148. Effects of ultraviolet radiation (UVR) on the skin 149. Skin cancer in organ-transplant recipients 150. Neurocutaneous disorders Answers VIVA questions References Abbreviations Index